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Consensus Review and Definition of Nonallergic Rhinitis
with a Focus on Vasomotor Rhinitis, Proposed to Be
Known henceforth as Nonallergic Rhinopathy
Part 1. Introduction
Michael A. Kaliner, MD,1,3 and Judith R. Farrar, PhD2
Abstract: “Nonallergic vasomotor rhinitis” (also referred to as
nonallergic rhinitis and/or idiopathic rhinitis) is a term that has been
used to describe a common nasal condition of unclear pathophysi-
ology. Clinical options for patients are limited by a lack of straight-
forward diagnostic criteria and poorly defined and heterogeneous
populations in clinical trials. A roundtable conference convened in
December 2008 addressed these challenges. The outcomes were (1)
a revised clinical definition and (2) appropriate inclusion and exclu-
sion criteria (based on the revised definition) to be used for the
enrollment of subjects in future clinical studies.
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The term nonallergic vasomotor rhinitis (also called idiopathicrhinitis) is generally agreed to describe rhinitis symptoms
that occur in relation to nonallergic, noninfectious triggers such
as (but not limited to) the following: changes in temperature,
humidity, and barometric pressure; exposure to strong odors,
tobacco smoke, and exhaust fumes; and even the ingestion of
certain foods. Up to one third of patients with rhinitis are
estimated to have nonallergic rhinitis, and close to 65% of
patients with allergic rhinitis also have symptoms that occur or
worsen in the presence of nonspecific, nonallergic stimuli.
The primary symptoms are nasal obstruction and rhi-
norrhea, with the term “vasomotor” suggesting involvement
of neural, glandular, and vascular pathways. However, the
term is misleading because it implies a known underlying
mechanism when in reality the pathophysiology is not estab-
lished. Additionally, the condition is associated with many
other variable symptoms, and there is confusion about spe-
cific diagnostic testing and appropriate treatment options for
these patients. The primary challenges associated with non-
allergic vasomotor rhinitis are (1) agreement upon a defini-
tion that adequately describes this disease and (2) establish-
ment of acceptable diagnostic criteria. An estimated 20 to 30
million Americans have this problem, and until criteria de-
fining the disease are established, clinical studies examining
effective treatment options are impossible to design.
In an attempt to address these challenges, a roundtable
conference was convened in Washington, D.C. in December
2008 with the dual goals of (1) clinically defining nonallergic
vasomotor rhinitis and then (2) using that definition to develop
appropriate inclusion and exclusion criteria for the enrollment of
subjects in future clinical studies.
Chaired by Michael A. Kaliner, MD, the consensus meeting
included James N. Baraniuk, MD, Michael Benninger, MD,
Jonathan A. Bernstein, MD, Phil Lieberman, MD, Eli O. Meltzer,
MD, Robert M. Naclerio, MD, and Russell A. Settipane, MD. Each
expert participant presented a state-of-the-art paper on a topic
related to what is currently known about the pathophysiology,
epidemiology, diagnostic criteria, and treatment options. The pre-
sentations were followed by discussion and counterpoints, leading
to two consensus statements: one on the definition and the other on
the study criteria. Our goal was to work toward improving our
understanding of the phenotypes to identify homogeneous popula-
tions for studying the underlying mechanisms and developing better
therapies. We have done that, and the findings, discussion, and
recommendations are presented in these proceedings.
The NAR Consensus Panel Proceedings have been divided
into 2 parts. Part 1, presented here, starts with an overview of the
classification of nonallergic rhinitis syndromes and the proposal to
change the terminology to reference these as “nonallergic rhinopa-
thy”; it ends with a detailed consensus definition of the new term.
However, this is presented with the caveat that the older terminol-
ogy remains in the individual papers as they were written and
submitted before the consensus discussion.
Part 2 includes papers on medications to treat nonallergic
rhinopathy and concludes with a consensus discussion of the inclu-
sion and exclusion criteria for clinical studies and remaining ques-
tions. This will be published in an upcoming issue of this journal.
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